

# VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

## Company



2024/08/15 22:00:00

Price

**472.00**

USD

Difference

0.12%(0.56)



## Contact Details

VERTEX PHARMACEUTICALS  
INC.

--

50 Northern Avenue

02210 Boston

Tel: +1-617-341-6100

Fax: +

Web: <http://www.vrtx.com>

E-mail:  
[mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

## Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023           |                        | 2022           |                        | 2021           |                        |
|--------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| Current assets                 | 14,144,200,000 |                        | 13,234,800,000 |                        | 9,560,600,000  |                        |
| Common stock capital           |                | 2,600,000              |                | 2,600,000              |                | 2,500,000              |
| Fixed assets                   | 8,942,100,000  |                        | 4,916,100,000  |                        | 3,871,900,000  |                        |
| Equity capital of a company    |                | 17,580,400,000         |                | 13,912,700,000         |                | 10,100,000,000         |
| Cash and cash equivalents      | 10,372,300,000 |                        | 10,512,000,000 |                        | 6,800,100,000  |                        |
| Accrued liabilities            |                | 0                      |                | 0                      |                | 0                      |
| Other assets                   | -              |                        | -              |                        | -              |                        |
| Current liabilities            |                | 3,547,400,000          |                | 2,742,100,000          |                | 2,142,000,000          |
| Prepayments and accrued income | -              |                        | -              |                        | -              |                        |
| Non-current liabilities        |                | 1,958,500,000          |                | 1,496,100,000          |                | 1,190,500,000          |
| Different income               |                | -                      |                | -                      |                | -                      |
| Other liabilities              |                | 309,700,000            |                | 685,800,000            |                | 303,300,000            |
| Total assets                   | 23,086,300,000 | 23,086,300,000         | 18,150,900,000 | 18,150,900,000         | 13,432,500,000 | 13,432,500,000         |

## Balance notes

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees           | 5,400   | 4,800   | 3,900   |
| Equity ratio        | 76.15%  | 76.65%  | 75.19%  |
| Debt-equity ratio   | 31.32%  | 30.46%  | 33.00%  |

## Others

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 17.36% | 21.51% | 14.22% |

# VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

## Income statement

|   | 2023          | 2022          | 2021          |
|---|---------------|---------------|---------------|
| Turnover  | 9,839,000,000 | 8,748,200,000 | 7,604,400,000 |
| Net income  | 3,619,600,000 | 3,322,000,000 | 2,342,100,000 |
| EBIT  | 3,464,467,400 | 3,767,694,700 | 2,534,776,500 |
| Operating income before taxes                                 | 4,379,800,000 | 4,232,400,000 | 2,730,400,000 |
| Cash Flow   | 3,537,300,000 | 4,129,900,000 | 2,643,500,000 |
| Net interest income   | 570,600,000   | 89,800,000    | -56,600,000   |
| Research and development expenses                             | 3,162,900,000 | 2,642,800,000 | 3,051,100,000 |
| Income taxes  | 760,200,000   | 910,400,000   | 388,300,000   |
| Result from investments in subsidiaries, associates and other | 0             | 0             | 0             |
| Revenues per employee   | 1,657,143     | 1,657,602     | 1,773,385     |

## Board of Directors

## Members of Management Board

|                    |                                |
|--------------------|--------------------------------|
| Jeffrey Leiden     | Chairman of Board of Directors |
| Alan Garber        | Member of Board of Directors   |
| Jennifer Schneider | Member of Board of Directors   |
| Sangeeta Bhatia    | Member of Board of Directors   |
| Bruce Sachs        | Member of Board of Directors   |
| Diana McKenzie     | Member of Board of Directors   |
| Lloyd Carney       | Member of Board of Directors   |
| Michel Lagarde     | Member of Board of Directors   |
| Nancy Thornberry   | Member of Board of Directors   |
| Suketu Upadhyay    | Member of Board of Directors   |
| Reshma Kewalramani | Chairman of Managing Board     |
| David Altshuler    | Member of Executive Committee  |
| Amit K. Sachdev    | Member of Executive Committee  |
| Bastiano Sanna     | Member of Executive Committee  |
| Carmen Bozic       | Member of Executive Committee  |
| Charles F. Wagner  | Member of Executive Committee  |
| E. Morrey Atkinson | Member of Executive Committee  |
| Jonathan Biller    | Member of Executive Committee  |
| Nia Tatsis         | Member of Executive Committee  |
| Stuart A. Arbuckle | Member of Executive Committee  |